Seeking Alpha

Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension

CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...
Nasdaq

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of ...
Nasdaq

AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection)

The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients WALTHAM, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- ...
Business Insider

Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)

CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Business Insider

AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ (Bremelanotide Injection) Data in Obstetrics & Gynecology

WALTHAM, Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and ...